Compare
Dermata Therapeutics, Inc. vs Processa Pharmaceuticals, Inc. vs GT Biopharma, Inc. vs Silo Pharma, Inc.
| Latest fiscal year | Dermata Therapeutics, Inc. DRMA | Processa Pharmaceuticals, Inc. PCSA | GT Biopharma, Inc. GTBP | Silo Pharma, Inc. SILO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $72.1K |
| Revenue growth (YoY) | n/a | n/a | n/a | 0.0% |
| Gross margin | n/a | n/a | n/a | 38.6% |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$7.56M | -$13.56M | -$28.35M | -$4.23M |
| EPS (Diluted) | -$8.16 | -$10.36 | -$6.68 | -$0.50 |
| Operating cash flow | -$7.76M | -$11.39M | -$12.91M | -$4.66M |
| Free cash flow | n/a | n/a | n/a | n/a |
| Cash & equivalents | $7.52M | $5.54M | $6.81M | $4.75M |
| Total assets | $7.86M | $7.81M | $8.11M | $7.61M |
| Total liabilities | $1.64M | $2.24M | n/a | $1.30M |
| Shareholders' equity | $6.22M | $5.58M | $5.79M | $6.31M |
| Return on year-end equity | -121.5% | -243.2% | -490.0% | -67.0% |
| Shares outstanding | 2.66M | 2.57M | 25.53M | 13.32M |
Revenue, most recent five fiscal years
| Fiscal year | Dermata Therapeutics, Inc. | Processa Pharmaceuticals, Inc. | GT Biopharma, Inc. | Silo Pharma, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2022-12-31 | $0 Ended 2020-12-31 | $72.1K Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2021-12-31 | $0 Ended 2019-12-31 | $72.1K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $72.1K Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $72.1K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | n/a |